Par Drugs and Chemicals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Par Drugs and Chemicals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Par Drugs and Chemicals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:PAR - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	956	145	142	202	N/A
12/31/2023	973	142	N/A	N/A	N/A
9/30/2023	962	127	140	227	N/A
6/30/2023	952	115	N/A	N/A	N/A
3/31/2023	957	113	57	134	N/A
12/31/2022	933	103	N/A	N/A	N/A
9/30/2022	873	106	32	76	N/A
6/30/2022	821	91	N/A	N/A	N/A
3/31/2022	751	92	44	76	N/A
12/31/2021	692	112	N/A	N/A	N/A
9/30/2021	686	112	4	67	N/A
6/30/2021	631	115	N/A	N/A	N/A
3/31/2021	608	116	70	121	N/A
12/31/2020	579	88	N/A	N/A	N/A
9/30/2020	550	83	102	120	N/A
6/30/2020	554	65	82	98	N/A
3/31/2020	558	48	61	77	N/A
12/31/2019	532	41	N/A	N/A	N/A
9/30/2019	506	20	12	17	N/A
6/30/2019	484	23	15	19	N/A
3/31/2019	463	25	30	34	N/A
3/31/2018	424	15	40	46	N/A
3/31/2017	488	18	N/A	92	N/A
3/31/2016	333	4	N/A	65	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PAR's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if PAR's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if PAR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAR's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if PAR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PAR's Return on Equity is forecast to be high in 3 years time

Par Drugs and Chemicals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Full year 2024 earnings released: EPS: ₹11.78 (vs ₹9.21 in FY 2023)

Now 23% overvalued after recent price rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.52 in 3Q 2023)

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Second quarter 2024 earnings released: EPS: ₹3.97 (vs ₹3.03 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 15%

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 16, 2023

First quarter 2024 earnings released: EPS: ₹2.01 (vs ₹1.86 in 1Q 2023)

Investor sentiment improves as stock rises 23%

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Full year 2023 earnings released: EPS: ₹9.21 (vs ₹7.49 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.72 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.03 (vs ₹1.80 in 2Q 2022)

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.86 (vs ₹1.90 in 1Q 2022)

Par Drugs and Chemicals Limited, Annual General Meeting, Sep 10, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹7.49 (vs ₹9.44 in FY 2021)

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Non Executive Director recently bought ₹304k worth of stock

CEO & Executive Director recently bought ₹313k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

CEO & Executive Director recently bought ₹199k worth of stock

CEO & Executive Director recently bought ₹189k worth of stock

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹1.25 per share

Second quarter 2022 earnings released: EPS ₹1.80 (vs ₹2.08 in 2Q 2021)

Investor sentiment deteriorated over the past week

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Full year 2021 earnings released: EPS ₹9.44 (vs ₹3.87 in FY 2020)

Investor sentiment improved over the past week

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Investor sentiment improved over the past week

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Investor sentiment improved over the past week

New 90-day high: ₹73.40

CEO & Executive Director recently bought ₹391k worth of stock

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Chairman of the Board & MD recently bought ₹263k worth of stock

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Investor sentiment improved over the past week

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Market bids up stock over the past week

New 90-day high: ₹55.90

New 90-day high: ₹51.00

New 90-day high: ₹50.45

New 90-day high - ₹50.00

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies